First Trust NASDAQ Pharmaceuticals ETF (FTXH)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
FTXH Chart
Could pressure to make money faster kill the next lifesaving pill?
When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.
Pharma ETF (FTXH) Hits New 52-Week High
Pharma ETF FTXH hits a new 52-week high as industry momentum, rate cuts, and AI adoption lift the sector???signaling potential near-term upside for FTXH investors.
A Look at Pharma ETFs After Strong Q1 Earnings
Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
First Trust NASDAQ Pharmaceuticals ETF Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MS Missy Straw Nilsine Partners LLC | 27,120 | $908,360 | $979,845.6 | $71,485.6 | 7.87% |
First Trust NASDAQ Pharmaceuticals ETF (FTXH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has First Trust NASDAQ Pharmaceuticals ETF ever had a stock split?
First Trust NASDAQ Pharmaceuticals ETF Profile
| NASDAQ (NMS) Exchange | US Country |
Overview
This fund primarily focuses on investing in the U.S. pharmaceutical sector, aiming to track the performance of a specific index composed of companies within this industry. The strategy involves allocating at least 90% of its net assets, including any investment borrowings, directly into the securities that make up the mentioned index. The selection criteria for these companies are mainly based on liquidity and their respective rankings within the sector. It is important to note that the fund adopts a non-diversified investment approach, concentrating its assets in the pharmaceutical sector to achieve its investment objectives.
Products and Services
- Index-Based Pharmaceutical Sector Exposure
This product offers investors targeted exposure to the U.S. pharmaceutical sector through securities that are included in the designated index. The fund's investment strategy ensures that a minimum of 90% of its assets are invested in these securities, aiming to replicate the performance of the index which is carefully selected based on specific criteria including liquidity and market ranking.
- Non-Diversified Investment Approach
Choosing a non-diversified approach, the fund focuses its investments in the pharmaceutical sector, which may involve higher risks due to the concentration of assets but also offers the potential for significant rewards. This strategy is ideal for investors seeking focused exposure to this sector, understanding the risks involved with a non-diversified portfolio.
